Eli Lilly and Co. received approval from U.S. FDA for Taltz® injection 80 mg/mL for the treatment of adult with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA).   This is the third indication for Taltz, which was first approved by the FDA in March 2016 for the treatment of moderate to severe plaque psoriasis in adult patients, and then approved by the FDA in December 2017 for the treatment of adults with active psoriatic arthritis.   The effic...